meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
mHCC - 1st line (L1)
4
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib
KRAS gene alteration targeted therapy
sotorasib
MET gene alteration targeted therapy
capmatinib
NTRK gene alteration targeted therapy
entrectinib
larotrectinib
RET gene alteration targeted therapy
pralsetinib
selpercatinib
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
avelumab based treatment
avelumab alone
cemiplimab
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs gemcitabine
vs taxanes
vs docetaxel
vs paclitaxel
vs nab-paclitaxel
vs vinca alkaloids
vs vinorelbine
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs gene alteration target therapy
vs ALK inhibitors
vs crizotinib
vs EGFR gene alteration
vs osimertinib
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs pembrolizumab based treatment
vs pembrolizumab alone
vs pembrolizumab (10mg/kg)
vs pembrolizumab plus placebo
vs pembrolizumab plus SoC
vs non active control
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
vs placebo plus BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
durvalumab based treatment
durvalumab alone
durvalumab alone
durvalumab plus osimertinib
Comparator:
vs placebo;
vs Standard of Care (SoC);
vs osimertinib;
Risk of bias:
low;
some concerns;
high;
NA;